Search This Blog

Tuesday, January 7, 2025

Sen. Marshall: Biden’s 11th-hour actions slap in the face to Trump voters

Sen. Roger Marshall (R-Kan.) says that President Biden’s moves in the final days of his presidency to ban offshore drilling, grant clemency to hundreds of Americans convicted of crimes, and reported efforts to negotiate a prisoner exchange with the Taliban are a “slap in the face” to Trump voters.

“This is a slap in the face of the 77 million Americans who voted for President Trump. And Americans are going to remember this,” Marshall declared during an interview with Fox Business’s Maria Bartiromo on Tuesday.

Marshall called Biden a “petty loser” when asked about President-elect Trump’s accusation that his predecessor is “doing everything possible to make the transition as difficult as possible.”

“They are petty losers. This flies in the face of Americans. And I can’t remember if you mentioned this, but what really irks, I think, the folks back in Kansas is President Biden pardoning people for crimes they’re not even charged with. I think that at our hearts, Americans know this is wrong,” he said.

News outlets reported last month that Biden’s team has discussed whether to issue pardons for administration officials and members of Congress whom they fear might be targeted for prosecution in the new Trump administration.

The Kansas senator also criticized Biden’s decision to ban new offshore oil and gas development along much of the nation’s coastlines and to announce nearly $2.5 billion in additional military aid for Ukraine.

“He is giving, he’s shoveling billions of dollars out the door before President Trump gets in there, giving us an even larger debt, really impacting our treasuries and the bond market,” he said.

“He’s making it darn hard for President Trump, but I just can’t wait till we get him inaugurated and we’ll try to reconcile all these issues,” Marshall added.

https://thehill.com/homenews/senate/5072503-biden-offshore-drilling-clemency/

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

 Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK (GSK) for H5N1 virus.

https://seekingalpha.com/news/4393173-arbutus-could-benefit-from-big-pharma-bird-flu-vaccines-jefferies

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

 Full year revenue of ~$84.6 million represents a 15% year-over-year increase

Cash balance of ~$185.0 million expected to provide runway to cash flow break-even

https://www.businesswire.com/news/home/20250107686915/en

Danish stocks mixed as Trump threatens tariffs to acquire Greenland

 President-elect Trump threatens tariffs on Denmark for Greenland bid, impacting Danish stocks such as Novo Nordisk.

https://seekingalpha.com/news/4393215-danish-stocks-mixed-as-trump-threatens-tariffs-to-acquire-greenland

CytomX Pipeline Priorities, Corporate Update

 - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -

- Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 -

- Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 -

- Company to present at 43rd Annual JP Morgan Healthcare Conference on January 15th -

https://www.globenewswire.com/news-release/2025/01/06/3004963/37704/en/CytomX-Therapeutics-Announces-2025-Strategic-Pipeline-Priorities-and-Provides-Corporate-Update.html

Arcturus Starts Phase 2 for Cystic Fibrosis, Ornithine Transcarbamylase (OTC) Deficiency

 First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024

Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025

https://www.businesswire.com/news/home/20250106386740/en/

Cardinal upped to Outperform from In-Line by Evercore

 Target $140

https://finviz.com/quote.ashx?t=CAH&p=d